FDA Announces Joint Meeting of Psychopharmacologic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee

Summary

The FDA is hosting a joint meeting of its Psychopharmacologic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee, seeking public input on regulatory issues, and is establishing a public docket for comments.